Carl Sterritt

Carl Sterritt Email and Phone Number

Co-founder and Chair @ PharmaKrysto
New Milton, GB
Carl Sterritt's Location
New Milton, England, United Kingdom, United Kingdom
About Carl Sterritt

A highly experienced pharmaceutical industry entrepreneur and executive with over 25 years of valuation creation and delivery in both private and public ownership environments. A creative, lateral thinker with proven entrepreneurial flair and a clear record of delivering shareholder value. Key strengths include business leadership experience, creation and delivery of effective business strategy, as well as effective communication and relationship building capabilities. Founder and erstwhile Board member/CEO of Shield Therapeutics plc, a speciality pharma company focused on the development and commercialisation of proprietary prescription medicines allow patients to be people again. I was the key investor contact, as well as having primary responsibility for the creation and delivery of the Company’s strategy. Key achievements in this role included:• Raising c. $150m of investment in both the private and public investor environments, including taking Shield through a successful IPO process in 2016 (LSE AIM: STX.L)• Acquiring and/or inbound licensing of novel pharmaceutical assets for development and commercialisation to the benefit of Shield’s shareholders• Leading the development and subsequent approval in the EU (EMA) and USA (FDA) of Shield’s primary asset, Feraccru/Accrufer as well as taking PT20 to Phase 3 readiness• Negotiating and executing numerous outbound licensing agreements of Shield’s Feraccru/Accrufer with pharmaceutical partners, realising more than £20m in upfront licence payments as well as setting up the opportunity for hundreds of millions of £ of milestone and royalty payments over the IP life of the asset• Extensive investor, analyst, shareholder and media communications• Building a deeply experienced, robust and adaptable international organisation with a ‘can do’ culture that was fit to successfully deal with a multitude of complex cultural, institutional regulatory issues common to a growing and ambitious entrepreneurial businessOn a personal level I am a results-focused and indefatigable individual who is a creative, lateral thinker with proven entrepreneurial flair that is matched to a clear record of delivering shareholder value. Key personal strengths include business leadership experience, decisiveness, effective delegation, creation and delivery of value-creating business strategies, effective communication skills and a strong relationship and team-builder with an ability to engender a highly inclusive, positive and committed corporate culture.

Carl Sterritt's Current Company Details
PharmaKrysto

Pharmakrysto

View
Co-founder and Chair
New Milton, GB
Carl Sterritt Work Experience Details
  • Pharmakrysto
    Co-Founder And Chair
    Pharmakrysto
    New Milton, Gb
  • Nunabio Limited
    Chair
    Nunabio Limited Sep 2024 - Present
    Newcastle Upon Tyne, Tyne And Wear, Gb
    NunaBio is a privately-owned specialist DNA synthesis and development company that makes custom DNA sequences that no one else can. The current pharmaceutical industry DNA production model is unable to keep up with the quantity, quality and complexity required for cutting-edge technologies. Synthetically produced DNA is therefore becoming an increasingly critical component for a wide range of emerging and established industries with global demand increasing rapidly.Our multi-patented technology produces synthetic DNA using enzymes rather than hazardous chemicals. It is cell-free, entirely in-house and scaleable with fast turnaround and the ability to produce complex sequences of high purity. Our DNA is suitable for a range of applications, including: DNA templates for mRNA, monoclonal antibodies, personalized medicines and gene therapies.SInce inception the company has built a solid reputation for our flexibility and an innovative approach to complex and challenging projects meaning our products are suitable for a variety of research and product developmental uses by the pharmaceutical industry.
  • Pharmakrysto
    Co-Founder And Chairman
    Pharmakrysto Jan 2016 - Present
    PharmaKrysto was founded by a highly experienced team of drug developers who were inspired to create the company when we understood what people with Cystinuria experience every day and how a new and effective therapy could positively change their lives.Our mission is to save kidneys and prevent pain in the adults and children with this life-changing condition who experience significant mental anguish as well as severe, frequent pain, kidney damage and a risk of kidney failure caused by chronically recurring deposits of large amino acid crystals in their kidneys.We have been working with scientists in the USA who have discovered a method of blocking the growth of cystine crystals, through the use of newly invented molecules which have the potential to become a medication that could be taken as a tablet and prevent the growth of these stones. The IP and technology - for which we have worldwide exclusivity to develop and commercialise - works in a completely different way to current therapies and we are working to turn it into an effective treatment that has none of the drawbacks or severe side effects of current treatments.
  • Livero Partners
    Entrepreneur And Strategic Advisor
    Livero Partners Apr 2020 - Jul 2024
    In business delivery is key. WIthout delivery value is destroyed and stakeholders quickly become disatisfied and disenfranchised. The primary aim of Livero Partners is to facilitate the effective, timely and value-creating delivery of our clients projects.
  • Lunac Therapeutics
    Strategic Advisor
    Lunac Therapeutics Sep 2020 - Dec 2023
    At LUNAC Therapeutics we're developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants. This remains a significant health problem and presents a multi-billion dollar oportunity to a company that can develop a technology that can provide better and safer outcomes for the millions of patients affected by these issues on a daily basis.Our focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in the stemming of bleeding (haemostasis).​LUNAC is a spin-out company from the University of Leeds, founded and supported by world-leading experts in blood coagulation. We have already received over £8m of financial backing from the British Heart Foundation, the Wellcome Trust, Innovate UK, Epidarex Capital and the University of Leeds and are working towards commencing human studies of our tehnology as quickly as possible.Visit www.lunactherapeutics.com for more info.
  • Shield Therapeutics
    Founder & Ceo
    Shield Therapeutics Dec 2008 - Apr 2020
    Gateshead Quays, Gb
    Shield Therapeutics plc is a UK-based and publicly-listed pharmaceutical company focused on developing and commercialising novel specialty prescription pharmaceuticals. Shield’s two leading assets are Feraccru®, which is approved in Europe for the treatment of iron deficiency anaemia, and PT20, a treatment for hyperphosphataemia which has successfully completed a 1st pivotal study, leaving one study to be completed before a marketing authorisation application. The company was founded by Carl Sterritt.
  • Encysive
    Director, European Commercial Operations
    Encysive Jul 2006 - Dec 2008
    Successfully led commercial operations of Encysive's European business until it was acquired by Pfizer. In this role all the country by country operations reported to me and I carried responsiblity for European wide sales targets and associated expense budgets.
  • Lung Rx, Inc
    Svp Development
    Lung Rx, Inc 2003 - 2006
    Having the backing of leading clinicians, whilst working for United Therapeutics (UT) I proposed to the CEO that we redevelop the Company's lead product (Remodulin), which was formulated for subcutaneous infusion, as an inhaled formulation. After much discussion the CEO agreed to my idea and we started operations as Lung Rx. This division of UT has subsequently gone on to develop this product, which now forms a major part of the perceived value of United Therapeutics' stock price as can be seen by the effective news on the inhaled development has on the company's stock performance. The product has been well received by the scientific community and is currently being assessed by regulatory agencies for marketing authorisation.
  • United Therapeutics
    Sr Vp Commercial Development And Md For Europe
    United Therapeutics 2000 - 2006
    Having worked with United Therapeutics on a contract basis through projects at Quintiles, I was approached by one of the founders of UT to set up the company's European operations. Therefore I became the 1st employee of the European company and led the business for 6 years as we grew our operations in this market. By the time I left, the company I had led was very welll respected by competitors and customers in the European PAH market, had enjoyed it's 1st marketing authorisation in Europe, was significantly increasing sales year on year, had signed multiple distribution deals with commercial partners and was beginning to build major infrastructure to use as a base to grow from.
  • Quintiles
    Project Manager
    Quintiles 1997 - 2000
    Durham, North Carolina, Us
    Instigated and managed multi-national clinical trials of candidate therapeutics

Carl Sterritt Skills

Biotechnology Start Ups Clinical Trials Pharmaceutical Industry Business Planning Strategy Product Development Management Mergers And Acquisitions Clinical Development Entrepreneurship Strategic Planning Life Sciences Pharmaceutical Sales Competitive Analysis Leadership Lifesciences Business Strategy

Carl Sterritt Education Details

  • Henley Business School
    Henley Business School
    Business
  • University Of Surrey
    University Of Surrey
    Clinical Toxicology
  • University Of Leeds
    University Of Leeds
    Biochemistry

Frequently Asked Questions about Carl Sterritt

What company does Carl Sterritt work for?

Carl Sterritt works for Pharmakrysto

What is Carl Sterritt's role at the current company?

Carl Sterritt's current role is Co-founder and Chair.

What is Carl Sterritt's email address?

Carl Sterritt's email address is cs****@****ics.com

What is Carl Sterritt's direct phone number?

Carl Sterritt's direct phone number is +44 191 511*****

What schools did Carl Sterritt attend?

Carl Sterritt attended Henley Business School, University Of Surrey, University Of Leeds.

What skills is Carl Sterritt known for?

Carl Sterritt has skills like Biotechnology, Start Ups, Clinical Trials, Pharmaceutical Industry, Business Planning, Strategy, Product Development, Management, Mergers And Acquisitions, Clinical Development, Entrepreneurship, Strategic Planning.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.